Sunfox Technologies Raises $7 Million to Take Its Spandan Pocket ECG From Dehradun to the World
Dehradun-based Sunfox Technologies has raised about $7 million in a Series A led by Ashish Kacholia, Lashit Sanghvi, Alchemy Capital and 3one4 Capital. It will scale its smartphone-linked Spandan ECG and expand internationally.
A medtech company from Dehradun has raised a Series A round to scale up a cardiac test that fits in a pocket. Sunfox Technologies, maker of the Spandan portable ECG platform, has raised about $7 million (around ₹67 crore) in a Series A round. The round was led by investor Ashish Kacholia, Lashit Sanghvi, Alchemy Capital and 3one4 Capital and announced on 7 October 2026.
The problem Spandan addresses
The electrocardiogram (ECG) is one of the most basic tests in cardiology. It records the heart's electrical activity and is often the first step in spotting a heart attack or a rhythm disorder. A standard 12-lead ECG machine is cheap by hospital standards. In much of rural India, though, the bottleneck is access: a machine, someone to run it, and a cardiologist to read the result quickly enough to matter.
Spandan tackles that with a small device that works with a smartphone. Health workers or patients record an ECG on the device, and the reading goes to doctors for remote interpretation. A clinic without a cardiologist can still get an expert opinion on a suspected cardiac event.
Scale so far
Sunfox says about 60,000 Spandan devices have been deployed across India, reaching more than 20,000 villages across states and union territories. Separate reports cite about 5 million patients screened annually and a presence in more than 15 countries. These are company figures, and they measure different things: devices, locations and screenings.
International expansion will depend on the regulatory requirements in each destination market. The funding report does not establish specific new overseas approvals.
What the money is for
The company says the Series A will fund:
- Wider deployment of Spandan across India.
- A global go-to-market team to support its international expansion.
- More investment in R&D, clinical evidence and engineering, including new cardiac technologies.
The focus on clinical evidence matters. For a diagnostic, peer-reviewed data on accuracy compared with standard 12-lead ECGs is what convinces cardiologists, hospital buyers and foreign regulators. Distribution alone will not.
The company
Sunfox was founded in 2016 by Rajat Jain, Arpit Jain, Sabit Rawat, Nitin Chandola and Saurabh Badola. It previously raised ₹15 crore in a pre-Series A round led by Venture Catalysts. Its location is unusual: most Indian medtech hardware startups are clustered in Bengaluru, Hyderabad, Pune or Delhi-NCR, not in Uttarakhand.
Why it matters
India's medtech sector still imports a large share of its devices. A smartphone-linked ECG product designed in India illustrates how connected diagnostics can extend clinical expertise beyond specialist centres. The commercial opportunity depends on credible clinical evidence, clinician interpretation and the regulatory requirements of each market. Wider distribution alone is not proof of improved health outcomes.